{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:06:44Z","timestamp":1771434404472,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.urolonc.2025.12.007","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:59:36Z","timestamp":1767761976000},"page":"110971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate cancer deaths will decrease by 2050"],"prefix":"10.1016","volume":"44","author":[{"given":"Nicholas N.","family":"Brutus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian J.","family":"Rabil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.urolonc.2025.12.007_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a030361","article-title":"The epidemiology of prostate cancer","volume":"8","author":"Pernar","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"21","key":"10.1016\/j.urolonc.2025.12.007_bib0002","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/cncr.35458","article-title":"Burden of 30 cancers among men: global statistics in 2022 and projections for 2050 using population-based estimates","volume":"130","author":"Bizuayehu","year":"2024","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2025.12.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33864","article-title":"Projected US urology workforce per Capita, 2020-2060","volume":"4","author":"Nam","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0004","series-title":"Prostate cancer. Statpearls","author":"Leslie","year":"2025"},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.007_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102298","article-title":"Trends and disparities in prostate cancer mortality in the United States (1999-2020)","volume":"23","author":"Aziz","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.007_bib0006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.urolonc.2025.12.007_bib0007","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM200105033441806","article-title":"Clinical practice. prostate-specific-antigen testing for early diagnosis of prostate cancer","volume":"344","author":"Barry","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.urolonc.2025.12.007_bib0008","doi-asserted-by":"crossref","first-page":"E301","DOI":"10.5489\/cuaj.8710","article-title":"Screening guidelines for individuals at increased risk for prostate cancer","volume":"18","author":"Lorentz","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221103988","article-title":"Biomarkers for prostate cancer detection and risk stratification","volume":"14","author":"Farha","year":"2022","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0010","article-title":"Cancer - screening and early detection","author":"Organization","year":"2010","journal-title":"Fact Sheets"},{"issue":"10","key":"10.1016\/j.urolonc.2025.12.007_bib0011","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1021\/acssensors.3c01402","article-title":"Point-of-care Prostate specific antigen testing: examining translational progress toward clinical implementation","volume":"8","author":"Garg","year":"2023","journal-title":"ACS Sens"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0012","doi-asserted-by":"crossref","unstructured":"Matsukawa A., Yanagisawa T., Bekku K., et al. Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2024;7(4):697\u2013704.","DOI":"10.1016\/j.euo.2023.12.005"},{"issue":"18","key":"10.1016\/j.urolonc.2025.12.007_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14184483","article-title":"A novel, quick, and reliable smartphone-based method for serum PSA quantification: original design of a portable microfluidic immunosensor-based system","volume":"14","author":"Ortega","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106618","article-title":"Optimization of prostate biopsy - Micro-ultrasound versus MRI (OPTIMUM): a 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer","volume":"112","author":"Klotz","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0015","doi-asserted-by":"crossref","unstructured":"Lu-Yao G.L., Albertsen P.C., Moore D.F., et al. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. JAMA Intern Med. 2014;174(9):1460\u20137.","DOI":"10.1001\/jamainternmed.2014.3028"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0016","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","article-title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"103","author":"Feyerabend","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.007_bib0017","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/03007995.2018.1447450","article-title":"Abiraterone acetate\/androgen deprivation therapy combination versus docetaxel\/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy","volume":"34","author":"Kassem","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ctrv.2019.01.002","article-title":"Therapeutic options for first-line metastatic castration-resistant prostate cancer: suggestions for clinical practise in the CHAARTED and LATITUDE era","volume":"74","author":"Tucci","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.12.007_bib0020","doi-asserted-by":"crossref","unstructured":"Drake C.G. Update on prostate cancer vaccines. Cancer J. 2011;17(5):294\u20139.","DOI":"10.1097\/PPO.0b013e3182325e78"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.007_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14040967","article-title":"Prospect of prostate cancer treatment: armed CAR-T or combination therapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.urolonc.2025.12.007_bib0022","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41585-018-0006-0","article-title":"Prostate cancer and social media","volume":"15","author":"Loeb","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.007_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41391-023-00684-0","article-title":"Artificial intelligence applications in prostate cancer","volume":"27","author":"Baydoun","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.007_bib0024","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41591-021-01620-2","article-title":"Artificial intelligence for diagnosis and gleason grading of prostate cancer: the PANDA challenge","volume":"28","author":"Bulten","year":"2022","journal-title":"Nat Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:16:25Z","timestamp":1771431385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1078143925004892"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer deaths will decrease by 2050","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110971"}}